期刊
LEUKEMIA & LYMPHOMA
卷 51, 期 12, 页码 2222-2229出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/10428194.2010.524327
关键词
Chronic lymphocytic leukemia; angiogenesis; vascular endothelial growth factor (VEGF); therapy; bevacizumab; receptor tyrosine kinase inhibitor
资金
- National Institutes of Health (NIH), National Cancer Institute (NCI) [CA113408, CA116237, N01-CM62205, CA25224, CA114740, CA15083, N01-CM62207]
- Commonwealth Foundation for Cancer Research
- Polyphenon E International
Between 2005 and 2008, we conducted separate phase II clinical testing of three distinct anti-VEGF therapies for patients with relapsed/refractory CLL. Collectively, 46 patients were accrued to trials of single-agent anti-VEGF antibody (bevacizumab, n = 13) or one of two receptor tyrosine kinase inhibitors (AZD2171, n = 15; sunitinib malate, n = 18). All patients have completed treatment. Patients received a median of two cycles of bevacizumab, AZD2171, or sunitinib malate. All three trials were closed early due to lack of efficacy. No complete or partial remissions were observed. Individually and collectively, these studies indicate that single-agent anti-VEGF therapy has minimal clinical activity for patients with relapsed/refractory CLL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据